Drug intelligence / Profile preview

MTB-1806

Development stage: Preclinical
Lead developer: Genuine Biotech
Modality: Small Molecules

Overview

MTB-1806 is a small molecule inhibitor of 15-lipoxygenase-2 (15-LOX-2) being developed by Bio Genuine for the treatment of acute ischemic stroke (AIS). 15-LOX-2 (also known as ALOX15B) is an enzyme that oxygenates polyunsaturated fatty acids, and its upregulation in the brain following ischemia is associated with neuronal death and inflammation. By inhibiting this enzyme, MTB-1806 is intended to exert neuroprotective effects and reduce secondary brain injury, thereby improving clinical outcomes in patients suffering from acute ischemic stroke.

Targets

ALOX15B (Arachidonate 15-lipoxygenase B)

Beyond the preview

Go deeper on MTB-1806.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTB-1806.

Explore the full profile